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Parkinson's diseaseBoth Gaucher disease patients and heterozygous glucocerebrosidase mutation carriers are at increased risk of
Parkinson's disease. Retinal thinning has been reported in early Parkinson's disease. Here we used optical coher-
ence tomography to demonstrate thinning of the retinal ganglion cell layer in Gaucher disease patients and
carriers who manifest clinical markers of potential early neurodegeneration. Optical coherence tomography
may help identify Gaucher disease patients and carriers at increased risk of developing Parkinson's disease.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Mutations in the glucocerebrosidase gene (GBA), which encodes the
lysosomal hydrolase deﬁcient in Gaucher disease (GD), are themost com-
mon risk factor for Parkinson's disease (PD) [1]. BothGDpatients andhet-
erozygous GBA mutation carriers have a signiﬁcantly increased risk of
developing PD [1]. Clinical markers of potential early neurodegeneration
include signs such as hyposmia, cognitive impairment andmotor slowing,
which have been associated with increased risk of developing a neurode-
generative disorder, chieﬂy PD [2]. However, it is acknowledged that
these signs are neither sensitive nor speciﬁc for prodromal PD, with sev-
eral non-neurological causes existing for hyposmia for example [2]. A sub-
set of GDpatients and carriersmanifests clinicalmarkers of potential early
neurodegeneration, such as hyposmia and parkinsonian motor signs [3].
Detection of retinal thinning by optical coherence tomography
(OCT) in PD has been described in multiple studies, which total sever-
al hundred patients and controls [4–9], with only a minority of stud-
ies reporting absence of retinal thinning in PD [10,11]. Retinal
thinning correlates with disease severity in PD and may serve as a
biomarker of disease progression in PD [4–9]. Retinal deposition of
Gaucher cells has been described in GD, but there are no systematic
studies of retinal pathology in this condition [12]. Here we utilizede terms of the Creative Com-
se, distribution and reproduc-
ource are credited.
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in GD patients and heterozygous GBAmutation carriers who manifest
clinical markers of potential early neurodegeneration.
2. Methods
Type I GD patients and heterozygousGBAmutation carriers, without
a clinically manifest neurodegenerative disorder, and matched controls
were recruited. Participants were assessed with the University of Penn-
sylvania Smell Identiﬁcation Test (UPSIT), Uniﬁed Parkinson's Disease
Rating Scale (motor subscale) and Montreal Cognitive Assessment
(MoCA). OCT was performed using Fourier domain OCT (RTVue-100,
Optovue Inc., Fremont, CA). OCT was performed with dilated pupils in
both eyes, after ensuring that intra-ocular pressure was normal and vi-
sual ﬁelds were full. The ganglion cell complex thickness (GCC), which
extends from the internal limiting membrane to the inner nuclear
layer, was measured as a marker of retinal thinning. Mean GCC thick-
ness was compared between groups using a one way ANOVA test and
post hoc testing with least squares difference test (IBM, PASW version
20.1). The most severely affected eye from each individual was
analysed. The most severely affected eye was deﬁned as that with the
thinnest GCC measurement. GD patients and carriers were split into 2
groups: 1 group who had potential clinical markers of prodromal
neurodegeneration and 1 group without abnormalities of these clinical
markers. The non-neurological controls were a third group.
2.1. Patients
Eleven GD patients (5 female, mean age 63.7 years, range
45–89 years, 6/11 N370S/N370S genotype and remainder N370S/served.
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N370S genotype) and 7 controls with no neurological disease matched
for age (mean age 67, range 51–85, p = 0.9 vs GD) and sex (4 female)
were studied. No study participant had evidence of retinopathy or glau-
coma on ophthalmoscopy and all had normal intraocular pressures to
exclude glaucoma. The GD patients had clinical features typical of Type
I disease such as visceromegaly, bone disease and blood dyscrasia but
no eyemovement disorders. Four GDpatients had clinicalmarkers of po-
tential early neurodegeneration: 1 with hyposmia (UPSIT score under
15th centile for age and sex), 1 with cognitive impairment (MoCA
score 23), 1 with hyposmia and cognitive impairment, 1 with parkinso-
nian motor signs (rest tremor and rigidity but no bradykinesia, which
therefore does notmeet Queen Square Brain Bank criteria for a diagnosis
of Parkinson's disease). Two carriers had hyposmia. None of the study
participants were smokers or had known disease of their upper airways
or head injury which might cause olfactory impairment. The age of the
GD patients and carriers with and without clinical markers of potential
early neurodegeneration did not differ (62.5 +/− 3.7 years versus
65.0 +/− 14 years, p = 0.81).2.2. Optical coherence tomography results
Oneway ANOVA demonstrated a signiﬁcant difference in GCC thick-
ness between groups (F = 4.01, p = 0.036). The mean GCC thickness
for GD patients and carriers without potential clinical markers of early
neurodegeneration (mean 92.4 +/− 5 μM) did not differ from controls
(mean 93.4 +/− 8 μM, p = 0.9). Mean GCC thickness for GD patients
and heterozygousGBAmutation carriers with potential clinical markers
of early neurodegeneration (83.2 +/− 6 μM) was signiﬁcantly less
than that of controls (p = 0.025) or GD patients and carriers without
potential clinical markers of early neurodegeneration (p = 0.021)
(Fig. 1). The difference in the mean GCC thickness remained signiﬁcant
after correcting for the participants' refractive error.Fig. 1. Mean ganglion complex thickness as measured by optical coherence tomogra-
phy. The mean ganglion complex thickness was signiﬁcantly lower in the group of
Gaucher disease patients and GBA mutation carriers who had clinical markers of po-
tential early neurodegeneration (bar marked neurological sign present) than in the
control group or the group of Gaucher disease patients and carrier without clinical
markers of potential early neurodegeneration (bar marked no neurological sign).
Above each bar is a representative heat map of the optical coherence tomography stud-
ies. Red areas represent ganglion complex thickness less than 1% of predicted for age
and sex, yellow areas less than 5% of predicted and green areas thickness greater
than 5% of predicted. The grey disc represents the fovea.3. Discussion
Here we provide in vivo OCT data showing retinal thinning in GD
and heterozygous GBA mutation carriers. The mechanisms leading to
retinal degeneration in GD and carriers are unclear. Work in our lab
has demonstrated that loss of glucocerebrosidase enzyme activity is
associated with oxidative stress and mitochondrial dysfunction [13],
which can be associated with retinal degeneration. Autophagy has
been reported to play a role in retinal ganglion cell death in a murine
model of the lysosomal storage disorder Niemann–Pick disease type C
[14]. Thus, a role for lysosomal pathology in retinal degeneration
warrants further investigation. Several studies have documented
thinning of the retina, including ganglion cell loss, in PD [4–9]. In
our cohort retinal thinning is associated with clinical markers of po-
tential early neurodegeneration in GD patients and heterozygous
GBA mutation carriers. This suggests that retinal thinning detected
by OCT may serve as a biomarker of increased risk of developing a
neurodegenerative disorder, such as PD, in this cohort. However,
this needs to be proven in larger, prospective trials. Clinicians should
be aware that GD and carriage of heterozygous GBAmutations can be
associated with retinal thinning and should include these in the dif-
ferential diagnosis of retinal pathology when appropriate.
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